{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T04:40:03Z","timestamp":1713933603301},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,24]]},"DOI":"10.1097\/qad.0b013e3283553719","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T06:56:54Z","timestamp":1336028214000},"page":"1653-1661","source":"Crossref","is-referenced-by-count":24,"title":["Virological responses during treatment for recent hepatitis C virus"],"prefix":"10.1097","volume":"26","author":[{"given":"Jason","family":"Grebely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Applegate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kaldor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/COH.0b013e32834b4974","article-title":"Transmission of HCV in HIV-positive populations.","volume":"6","author":"Danta","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/sti.2009.038182","article-title":"Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia.","volume":"86","author":"Jin","year":"2010","journal-title":"Sex Transm Infect"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/431486","article-title":"Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study.","volume":"41","author":"Rauch","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/518796","article-title":"Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission.","volume":"196","author":"van de Laar","year":"2007","journal-title":"J Infect Dis"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/cid\/ciq201","article-title":"Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials.","volume":"52","author":"Taylor","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0b013e3281053a0c","article-title":"Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours.","volume":"21","author":"Danta","year":"2007","journal-title":"AIDS"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2893.2006.00802.x","article-title":"A short course of pegylated interferon-alpha in acute HCV hepatitis.","volume":"14","author":"Calleri","year":"2007","journal-title":"J Viral Hepat"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jhep.2004.11.018","article-title":"Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.","volume":"42","author":"Broers","year":"2005","journal-title":"J Hepatol"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.","volume":"39","author":"Kamal","year":"2004","journal-title":"Hepatology"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.21197","article-title":"Duration of peginterferon therapy in acute hepatitis C: a randomized trial.","volume":"43","author":"Kamal","year":"2006","journal-title":"Hepatology"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1053\/j.gastro.2006.01.034","article-title":"Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.","volume":"130","author":"Kamal","year":"2006","journal-title":"Gastroenterology"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MEG.0b013e328330a8e8","article-title":"Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort.","volume":"22","author":"Morin","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3851\/IMP1843","article-title":"Pegylated interferon-alpha monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.","volume":"16","author":"Arends","year":"2011","journal-title":"Antivir Ther"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350601100817","article-title":"Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.","volume":"11","author":"Vogel","year":"2006","journal-title":"Antivir Ther"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/hep.23850","article-title":"Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.","volume":"52","author":"Grebely","year":"2010","journal-title":"Hepatology"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","article-title":"Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index.","volume":"87","author":"Darke","year":"1992","journal-title":"Br J Addict"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jhep.2010.10.033","article-title":"Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.","volume":"55","author":"Grebely","year":"2011","journal-title":"J Hepatol"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/605444","article-title":"Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.","volume":"200","author":"McGovern","year":"2009","journal-title":"J Infect Dis"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/hep.23959","article-title":"Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study.","volume":"52","author":"Piroth","year":"2010","journal-title":"Hepatology"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C.","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.23985","article-title":"Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","article-title":"Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response.","volume":"46","author":"Feld","year":"2007","journal-title":"Hepatology"},{"key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.","volume":"37","author":"Herrmann","year":"2003","journal-title":"Hepatology"},{"key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.21657","article-title":"Triphasic decline of hepatitis C virus RNA during antiviral therapy.","volume":"46","author":"Dahari","year":"2007","journal-title":"Hepatology"},{"key":"R35-8-20210130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e3283553719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T04:12:41Z","timestamp":1713931961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201208240-00008"}},"subtitle":["potential benefit for ribavirin use in HCV\/HIV co-infection"],"short-title":[],"issued":{"date-parts":[[2012,8,24]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3283553719","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,24]]}}}